07:00 , Oct 27, 2008 |  BC Week In Review  |  Company News

Roskamp Institute neurology news

The Roskamp Institute spun outs its Alzheimer disease (AD) treatments into newco Archer Pharmaceuticals Inc. Archer's pipeline includes ARC029 and ARC031. The company plans to begin Phase I trials of ARC029, a formulation of nilvadipine,...